BANNOCKBURN, Ill., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, announced today financial results for the fourth quarter and full year ended December 31, 2023.
Fourth Quarter 2023 Financial Highlights
Net revenue of $1,124.4 million, up 9.5% compared to $1,027.2 million in the fourth quarter of 2022
Gross profit of $247.1 million, or 22.0% of revenue, up 6.9% compared to $231.1 million, or 22.5% of revenue, in the fourth quarter of 2022
Net income of $57.2 million, or $0.32 earnings per share, inclusive of the impact from non-operating income, compared to net income of $47.5 million, or $0.26 earnings per share in the fourth quarter of 2022
Adjusted EBITDA of $111.6 million, up 18.4% compared to $94.3 million in the fourth quarter of 2022
Cash flow from operations of $51.0 million, and cash balances of $343.8 million at the end of the fourth quarter
The Company announced that it fulfilled $250 million in share repurchases and the Board of Directors authorized an additional $250 million share repurchase authorization
Full Year 2023 Financial Highlights
Net revenue of $4,302.3 million, up 9.1% compared to $3,944.7 million in full year 2022
Gross profit of $981.2 million, or 22.8% of revenue, up 13.2% compared to $866.9 million, or 22.0% of revenue, in full year 2022
Net income of $267.1 million, or $1.48 diluted earnings per share, compared to net income of $150.6 million, or $0.83 earnings per share, in full year 2022
Adjusted EBITDA of $425.2 million, up 24.0% compared to $342.9 million in full year 2022
Cash flow from operations of $371.3 million, up 38.8% compared to $267.5 million in full year 2022
John C. Rademacher, Chief Executive Officer, commented, “The Option Care Health team delivered strong financial results in the fourth quarter and full year of 2023 and continued to execute on our commitment to clinical excellence by providing extraordinary patient care through our resilient national platform. The patient is at the center of everything we do, and I am excited to build on this momentum in 2024 to further our mission to provide innovative services that improve outcomes, reduce costs, and deliver hope for patients and families.”
Full Year 2024 Financial Guidance
For the full year 2024, Option Care Health expects to deliver the following financial results:
Net revenue of $4.6 billion to $4.8 billion
Adjusted EBITDA of $425 million to $450 million
Cash flow from operations of at least $300 million
Additionally, the Company anticipates an effective tax rate of 26% - 28% and net interest expense of approximately $55 million to $60 million.
Conference Call
Option Care Health will host a conference call to discuss its financial results later today at 8:30 a.m. EST. The conference call can be accessed via a live audio webcast that will be available online at investors.optioncarehealth.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.
About Option Care Health
Option Care Health is the nation’s largest independent provider of home and alternate site infusion services. With over 7,500 team members, including more than 4,500 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and teammates. To learn more, please visit our website at OptionCareHealth.com.
This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements include, among others, statements we may make regarding future revenues, future earnings, regulatory developments, market developments, new products and growth strategies, integration activities and the effects of any of the foregoing on our future results of operations or financial conditions.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: changes in laws and regulations applicable to our business model; changes in market conditions and receptivity to our services and offerings; pending and future litigation; potential liability for claims not covered by insurance; and loss of relationships with managed care organizations and other non-governmental third party payers. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our periodic reports as filed with the SEC.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Note Regarding Use of Non-GAAP Financial Measures
In addition to reporting financial information in accordance with generally accepted accounting principles (GAAP), the Company is also reporting Adjusted EBITDA, which is a non-GAAP financial measure. Adjusted EBITDA is not a measurement of financial performance under GAAP and should not be used in isolation or as a substitute or alternative to net income, operating income or any other performance measure derived in accordance with GAAP, or as a substitute or alternative to cash flow from operating activities or a measure of the Company’s liquidity. In addition, the Company's definition of Adjusted EBITDA may not be comparable to similarly titled non-GAAP financial measures reported by other companies. Adjusted EBITDA, as defined by the Company, represents net income before net interest expense, income tax expense, depreciation and amortization, stock-based compensation expense, loss on extinguishment of debt, and restructuring, acquisition, integration and other. As part of restructuring, acquisition, integration and other, the Company may incur significant charges such as the write down of certain long‑lived assets, temporary redundant expenses, professional fees, potential retention and severance costs and potential accelerated payments or termination costs for certain of its contractual obligations. Management believes that Adjusted EBITDA provides useful supplemental information regarding the performance of Option Care Health’s business operations and facilitates comparisons to the Company’s historical operating results. We have not reconciled Adjusted EBITDA guidance to net income as management believes creation of this reconciliation would not be practicable due to the uncertainty regarding, and potential variability of, material reconciling items. For a full reconciliation of Adjusted EBITDA to the most comparable GAAP financial measure, please see below.
Schedule 1
OPTION CARE HEALTH, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (IN THOUSANDS)(UNAUDITED)
December 31,
2023
2022
ASSETS
CURRENT ASSETS:
Cash and cash equivalents
$
343,849
$
294,186
Accounts receivable, net
377,658
377,542
Inventories
274,004
224,281
Prepaid expenses and other current assets
98,744
98,330
Total current assets
1,094,255
994,339
NONCURRENT ASSETS:
Property and equipment, net
120,630
108,321
Intangible assets, net
20,092
22,371
Referral sources, net
315,304
341,744
Goodwill
1,540,246
1,533,424
Other noncurrent assets
126,508
112,737
Total noncurrent assets
2,122,780
2,118,597
TOTAL ASSETS
$
3,217,035
$
3,112,936
LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES:
Accounts payable
$
426,513
$
378,763
Other current liabilities
191,796
186,588
Total current liabilities
618,309
565,351
NONCURRENT LIABILITIES:
Long-term debt, net of discount, deferred financing costs and current portion
1,056,650
1,058,204
Other noncurrent liabilities
120,404
103,278
Total noncurrent liabilities
1,177,054
1,161,482
Total liabilities
1,795,363
1,726,833
STOCKHOLDERS' EQUITY
1,421,672
1,386,103
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY
$
3,217,035
$
3,112,936
Schedule 2
OPTION CARE HEALTH, INC. CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS (IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)(UNAUDITED)
Three Months Ended December 31,
Year Ended December 31,
2023
2022
2023
2022
NET REVENUE
$
1,124,390
$
1,027,213
$
4,302,324
$
3,944,735
COST OF REVENUE
877,267
796,132
3,321,101
3,077,817
GROSS PROFIT
247,123
231,081
981,223
866,918
OPERATING COSTS AND EXPENSES:
Selling, general and administrative expenses
147,783
148,351
607,427
566,122
Depreciation and amortization expense
14,784
14,538
59,201
60,565
Total operating expenses
162,567
162,889
666,628
626,687
OPERATING INCOME
84,556
68,192
314,595
240,231
OTHER INCOME (EXPENSE):
Interest expense, net
(12,432
)
(14,798
)
(51,248
)
(53,806
)
Other, net
6,801
11,387
95,395
19,343
Total other (expense) income
(5,631
)
(3,411
)
44,147
(34,463
)
INCOME BEFORE INCOME TAXES
78,925
64,781
358,742
205,768
INCOME TAX EXPENSE
21,748
17,252
91,652
55,212
NET INCOME
$
57,177
$
47,529
$
267,090
$
150,556
Earnings per share, basic
$
0.32
$
0.26
$
1.49
$
0.83
Earnings per share, diluted
$
0.32
$
0.26
$
1.48
$
0.83
Weighted average common shares outstanding, basic
176,055
181,925
178,973
181,105
Weighted average common shares outstanding, diluted
177,743
183,086
180,375
182,075
Schedule 3
OPTION CARE HEALTH, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (IN THOUSANDS)(UNAUDITED)
Year Ended December 31,
2023
2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income
$
267,090
$
150,556
Adjustments to reconcile net income to net cash provided by operations:
Depreciation and amortization expense
62,200
65,434
Deferred income taxes - net
12,766
49,187
Other non-cash adjustments
50,684
32,147
Changes in operating assets and liabilities:
Accounts receivable, net
224
(36,889
)
Inventories
(51,000
)
(41,010
)
Accounts payable
47,703
98,885
Other
(18,372
)
(50,763
)
Net cash provided by operating activities
371,295
267,547
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of property and equipment
(41,866
)
(35,358
)
Proceeds from sale of assets
3,743
14,670
Business acquisitions, net of cash acquired
(12,494
)
(87,364
)
Other investing activities
(5,889
)
—
Net cash used in investing activities
(56,506
)
(108,052
)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from warrant exercises
—
20,916
Purchase of company stock
(250,261
)
—
Other financing activities
(14,865
)
(5,648
)
Net cash (used in) provided by financing activities
(265,126
)
15,268
NET INCREASE IN CASH AND CASH EQUIVALENTS
49,663
174,763
Cash and cash equivalents - beginning of the period
294,186
119,423
CASH AND CASH EQUIVALENTS - END OF PERIOD
$
343,849
$
294,186
Schedule 4
OPTION CARE HEALTH, INC. RECONCILIATION BETWEEN GAAP AND NON-GAAP MEASURES (IN THOUSANDS)(UNAUDITED)
Three Months Ended December 31,
Year Ended December 31,
2023
2022
2023
2022
Net income
$
57,177
$
47,529
$
267,090
$
150,556
Interest expense, net
12,432
14,798
51,248
53,806
Income tax expense
21,748
17,252
91,652
55,212
Depreciation and amortization expense
15,777
15,711
62,200
65,434
EBITDA
107,134
95,290
472,190
325,008
EBITDA adjustments
Stock-based incentive compensation expense
7,571
4,202
30,479
16,783
Gain on sale of assets
—
(10,325
)
—
(10,325
)
Restructuring, acquisition, integration and other (1)
(3,103
)
5,105
(77,486
)
11,387
Adjusted EBITDA
$
111,602
$
94,272
$
425,183
$
342,853
(1) Restructuring, acquisition, integration and other for the year ended December 31, 2023 includes the Amedisys merger termination fee, net of merger-related expenses
